Is Simponi Approved for Arthritis?
Yes, Simponi (golimumab) is FDA-approved for treating several forms of arthritis, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in adults. It targets tumor necrosis factor (TNF) to reduce inflammation and joint damage.[1][2]
How Does Simponi Treat Arthritis?
Simponi is given by subcutaneous injection every 4 weeks. For moderate-to-severe rheumatoid arthritis, it's used with methotrexate; alone for psoriatic arthritis or ankylosing spondylitis. Clinical trials showed it improves symptoms, physical function, and inhibits joint damage progression.[2][3]
What Arthritis Types Does It Cover?
- Rheumatoid arthritis: Reduces signs/symptoms and slows structural damage in active cases.
- Psoriatic arthritis: Improves joint/nail/skin symptoms.
- Ankylosing spondylitis: Relieves spinal inflammation and stiffness.
Not approved for osteoarthritis or juvenile idiopathic arthritis.[2]
Common Side Effects and Risks
Patients report injection-site reactions, upper respiratory infections, and increased infection risk due to immune suppression. Serious risks include tuberculosis reactivation, fungal infections, and rare lymphoma. Monitoring for infections is required.[2][4]
How Does Simponi Compare to Other TNF Inhibitors?
Simponi offers similar efficacy to Humira (adalimumab) or Enbrel (etanercept) but with less frequent dosing. Head-to-head trials show comparable ACR20 response rates (60-70% at 6 months). Choice depends on insurance, administration preference, and response.[3][5]
Who Makes Simponi and What's the Patent Status?
Janssen Biotech (Johnson & Johnson) manufactures Simponi. U.S. patents cover the drug until around 2025-2030 for key formulations, with ongoing litigation delaying biosimilars. Check DrugPatentWatch.com for expiry details and challenges.6
[1]: FDA Label for Simponi (golimumab), 2023.
[2]: Simponi.com official prescribing information.
[3]: Arthritis Foundation on TNF inhibitors.
[4]: Mayo Clinic drug database.
[5]: New England Journal of Medicine, GO-FURTHER trial, 2009.
[6]: Janssen press releases.